ERBB2 and neoplasm: While TNBC may be sensitive to RT initially, resistance often develops at later stages [12] due to significant intra-tumor cell heterogeneity [13, 14] and potential phenotypic switching due to cellular plasticity (e.g., from Her2- to Her2+) [15].